Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 27;16(2):463-470.
doi: 10.4240/wjgs.v16.i2.463.

Immune function status of postoperative patients with colon cancer for predicting liver metastasis

Le Xiong  1 , Fang-Chen Liu  2
Affiliations

Immune function status of postoperative patients with colon cancer for predicting liver metastasis

Le Xiong et al. World J Gastrointest Surg. .

Abstract

Background: Colon cancer (CC) has a high incidence rate. Radical resection is the main treatment method for CC; however, liver metastasis (LM) often occurs post-surgery. The liver contains both innate and adaptive immune cells that monitor and remove abnormal cells and pathogens. Before LM, tumor cells secrete cytokines and exosomes to adjust the immune microenvironment of the liver, thus forming an inhibitory immune microenvironment for colonization by circulating tumor cells. This indicates that the immune state of patients with CC plays a crucial role in the occurrence and progression of LM.

Aim: To observe and analyze the relationship between immune status and expression of tumor factors in patients with LM of CC, and to provide a scientific intervention method for promoting the patient prognosis.

Methods: A retrospective analysis was performed. The baseline data of 100 patients with CC and 100 patients with CC who suffered from postoperative LM and were admitted to our hospital from May 2021 to May 2023 were included in the non-occurrence and occurrence groups, respectively. The immune status of the patients and the expression of tumor factor-related indicators in the two groups were compared, and the predictive value of the indicators for postoperative LM in patients with CC was analyzed.

Results: Compared with the non-occurrence group, the expression of serum carcinoembryonic antigen (CEA), CA19-9, CA242, CA72-4 and CA50 in patients in the occurrence group were significantly higher, while the expression of CD3+, CD4+, CD8+, natural killer (NK) and CD4+/CD25 in patients in the occurrence group were significantly lower (P < 0.05). No significant difference was observed in other baseline data between groups (P > 0.05). Multivariate logistic regression model analysis revealed that the expressions of CEA, CA19-9, CA242, CA72-4, CA50, CD3+, CD4+, CD8+, NK, and CD4+/CD25 were associated with the LM in patients with CC. High expressions of serum CEA, CA19-9, CA242, CA72-4 and CA50, and low expressions of CD3+, CD4+, CD8+, NK, and CD4+/CD25 in patients with CC were risk factors for LM (OR > 1, P < 0.05). The receiver operating characteristic curve showed that the area under curve for CEA, CA19-9, CA242, CA72-4, CA50, CD3+, CD4+, CD8+, NK, and CD4+/CD25 in the prediction of LM in patients with CC were all > 0.80, with a high predictive value.

Conclusion: The expression of tumor factors and immune state-related indices in patients with CC is closely associated with the occurrence of LM.

Keywords: Colon cancer; Immune status; Liver metastases; Predicted value; Tumor factors.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: All authors have no conflicts of interest.

Figures

Figure 1
Figure 1
Receiver operating characteristic curve. A: Receiver operating characteristic (ROC) curve of tumor factor-related indices for predicting liver metastasis in patients with colon cancer; B: ROC curve of immune state-related indicators for predicting liver metastasis in patients with colon cancer. ROC: Receiver operating characteristic; CEA: Carcinoembryonic antigen; NK: Natural killer.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Christou N, Bergen ES, Canton C, Le Malicot K, Di Bartolomeo M, Galli F, Labianca R, Shi Q, Alberts SR, Goldberg RM, Lepage C, Sinicrope FA, Taieb J. Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients-A pooled analysis of three adjuvant trials. Eur J Cancer. 2022;166:100–111. - PubMed
    1. Taylor AS, Liu N, Fang JM, Panarelli N, Zhao L, Cheng J, Gopal P, Hammer S, Sun J, Appelman H, Westerhoff M. Cribriform colon cancer: a morphological growth pattern associated with extramural venous invasion, nodal metastases and microsatellite stability. J Clin Pathol. 2022;75:483–487. - PubMed
    1. Shaib WL, Zakka KM, Jiang R, Yan M, Alese OB, Akce M, Wu C, Behera M, El-Rayes BF. Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer. Cancer. 2020;126:4136–4147. - PubMed
    1. Stewart L, Indukuri VV, Charepalli V, Chrisfield BJ, Anantheswaran RC, Lambert JD, Vanamala JKP. Comparative effects of vacuum or conventional frying on the polyphenol chemistry and in vitro colon cancer stem cell inhibitory activity of purple-flesh potatoes. J Food Sci. 2022;87:3260–3267. - PubMed
    1. Lin YZ, Cheng HH, Huang SC, Chang SC, Lan YT. Comparison of two-stage and three-stage surgery for obstructing left-sided colon cancer. ANZ J Surg. 2022;92:1466–1471. - PubMed